Kallistatin levels in HIV-infected patients and effects of statin therapy.

Allison Ross Eckard, Soohee Cho, Mary Ann O'Riordan, Grace A McComsey

Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2017;22(1):55-62

PMID: 27326658

Free Full Text on PubMed Central View on PubMed

Abstract

BACKGROUND

Kallistatin, a serine proteinase inhibitor, has vasodilatory and anti-inflammatory properties and is increased in other inflammatory conditions. We measured kallistatin in HIV for the first time, examined its relationship with inflammation, and determined if statin therapy affected levels.

METHODS

Kallistatin levels were measured in subjects from a randomized, double-blinded, placebo-controlled trial.

RESULTS

One hundred and thirty-five HIV-infected subjects were included. Kallistatin levels were 28.4 μg/mL at baseline and not affected by rosuvastatin. Levels were correlated with high-sensitivity C-reactive protein (hsCRP), interleukin-6, fibrinogen and insulin resistance.

CONCLUSIONS

Kallistatin levels were correlated with some markers of systemic inflammation and should be further explored in the HIV population.

Address: a Department of Medicine, Division of Pediatric Infectious Diseases, Emory University School of Medicine , Atlanta , GA , USA.; b Departments of Medicine and Pediatrics, Divisions of Infectious Diseases, Medical University of South Carolina , Charleston , SC , USA.; c Departments of Medicine and Pediatrics, Divisions of Infectious Diseases, Case Western Reserve University and University Hospitals Case Medical Center , Cleveland , OH , USA.

DOI: 10.1080/1354750X.2016.1204002